APR 29 CTGTAC-ODAC

Results Wire: US FDA Advisory Committee Supports Amgen’s T-Vec to Treat Metastatic Melanoma – APR 29, 2015 (CTGTAC-ODAC)

On Wednesday, April 29, 2015, the Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) and the Oncologic Drugs Advisory Committee (ODAC) jointly supported, by a vote of 22-Yes to 1-No, the safety and efficacy of talimogene laherparepvec (T-Vec), submitted by Amgen, Inc. (Amgen). T-Vec is an oncolytic immunotherapy proposed for the treatment of patients with injectable regionally or distantly metastatic melanoma.

See the SAC Tracker Report